ClinicalTrials.gg
RecruitingNCT05985317Updated Aug 14, 2023

Effect of Collagen Versus PRF on BMA Osteogenic Potential

An interventional study of Collagen membrane over BMAC/bovine graft in sinus lift and PRF membrane over BMAC/bovine graft in sinus lift in Bone Loss, Alveolar, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jan 2023, registered Jul 2023).
  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Alveolar Bone Loss by Cairo University — 10 open to participants now, 11 under way, none of them phase 3. Alveolar Bone Loss · Cairo University.

Planned enrollment
30th of 30
2 · median 20
Started
2023
with 1 other
No phase
29 of 30
10 open now
Primary completion
2023-08
later than 0 of 10 live
Registered
17th of 30
by date

Among the 30 studies in Alveolar Bone Loss by Cairo University, this one is the 30th largest by planned enrollment, is one of 2 that started in 2023, is one of 29 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 17th registered.

Alveolar Bone Loss

320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

10 of the 30 studies in Alveolar Bone Loss by Cairo University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Alveolar Bone Loss by Cairo University, or all of them as a file.
02

Study summary

Utilization of collagen vs PRF membrane over the graft following sinus lift procedure and before suturing

Read the detailed description

Assessment of the effect of membrane overlying bone marrow aspirate concentrate - bovine graft mixture in sinus lift procedure

03

Conditions studied

  • Bone Loss, Alveolar

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who has as deficient as 4 mm vertical bone height in posterior maxilla that need bone augmentation before delayed implant placement.
  • Highly motivated patients
  • Age more than 18 years

Exclusion criteria

Exclusion Criteria:

  • Patients suffering from any systemic disease or those under any medication that may interfere with normal bone healing.
  • Patients suffering from any sinus pathosis.
  • Patients with conditions that could potentially compromise Bone Marrow ( BM)quality, including history of hematologic , current chemotherapy, BM suppressive and anti- medications, previous BM Aspiration, or acute illness.
  • Heavy smoker (> 20 cigarettes daily)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
2 participants (estimated)

Study arms

  • Active comparator
    Collagen membrane covering BMAC loaded on bovine graft

    Collagen membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative

    Procedure: Collagen membrane over BMAC/bovine graft in sinus lift

  • Active comparator
    PRF membrane covering BMAC loaded on bovine graft

    Platelet rich fibrin membrane will be used to BMAC loaded on bovine graft . Variables include assessment of the osteogenic potential In terms of bone density measurements of graft immediate and 4 months Postoperative

    Procedure: PRF membrane over BMAC/bovine graft in sinus lift

Interventions

  • ProcedureCollagen membrane over BMAC/bovine graft in sinus lift

    Collagen membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure

  • ProcedurePRF membrane over BMAC/bovine graft in sinus lift

    PRF membrane to cover BMAC/bovine graft in sinus lift and evaluation of its effect on osteogenic potential of BMAC in sinus lift procedure

06

What researchers measure

Primary outcomes

  1. Radiographic Bone density assessment

    Bone density measurements on Cone beam CT/CBCT immediate and 4 months radiographic density measurements in haunsfield units, immediate and 4 months postoperative

    Time frame: 4 months ( immediate - 4 months postoperative)

Secondary outcomes

  1. Radiographic Bone height assessment

    Assessment of bone hight on CBCT, mmediate and at 4 months postoperative

    Time frame: 4 months ( immediate - 4 months postoperative)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2023, 7 months after the start.

Of 169 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 7 months is below that.

Counting every sponsor, half of 169 studies reached it within 18 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2023
First posted
Aug 14, 2023
StartActual
Jan 25, 2023
Primary completionEst.
Aug 30, 2023
CompletionEst.
Aug 30, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05985317
Lead sponsor
Cairo University
Responsible party
Walaa Kadry (Lecturer of oral and Maxillofacial Surgery, Cairo University) — Principal investigator
First posted
Aug 14, 2023
Start date
Jan 25, 2023
Primary completion
Aug 30, 2023 (estimated)
Completion
Aug 30, 2023 (estimated)
Last update
Aug 14, 2023

Study contacts

Walaa Kadry
Contact
walaakadry@dentistry.cu.edu.eg
+201061527359
Abmed Amin
Contact
ahmamin2001.aa@gmail.com
+201061527358
Eman Said
study director · Lecturer at Faculty of Dentistry, Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion